284 related articles for article (PubMed ID: 32366905)
1. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
2. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
3. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
4. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
6. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
[TBL] [Abstract][Full Text] [Related]
7. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
[TBL] [Abstract][Full Text] [Related]
8. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
Liao S; Maertens O; Cichowski K; Elledge SJ
Genes Dev; 2018 Sep; 32(17-18):1188-1200. PubMed ID: 30135075
[TBL] [Abstract][Full Text] [Related]
9. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
11. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Fang W; French CA; Cameron MJ; Han YD; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
[TBL] [Abstract][Full Text] [Related]
12. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of NUT midline carcinoma.
French CA
Annu Rev Pathol; 2012; 7():247-65. PubMed ID: 22017582
[TBL] [Abstract][Full Text] [Related]
14. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
17. The importance of diagnosing NUT midline carcinoma.
French CA
Head Neck Pathol; 2013 Mar; 7(1):11-6. PubMed ID: 23463074
[TBL] [Abstract][Full Text] [Related]
18. "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Shiota H; Elya JE; Alekseyenko AA; Chou PM; Gorman SA; Barbash O; Becht K; Danga K; Kuroda MI; Nardi V; French CA
Mol Cancer Res; 2018 Dec; 16(12):1826-1833. PubMed ID: 30139738
[TBL] [Abstract][Full Text] [Related]
19. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
Yan J; Diaz J; Jiao J; Wang R; You J
J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
[TBL] [Abstract][Full Text] [Related]
20. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
